


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 “CEACAM5/4-1BB
BISPECIFIC ANTIBODY” APPROVED BY THE NMPA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that LM-24C5 “CEACAM5/4-1BB bispecific antibody”, an innovative drug independently developed by LaNova Medicines Limited (“**LaNova Medicines**”, a wholly-owned subsidiary of the Group), has received the clinical trial approval from the National Medical Products Administration (NMPA) of China for conducting Phase II clinical trials in patients suffering CEACAM5-positive advanced solid tumors in combination with other anti-tumor drugs.

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) is highly expressed in various types of solid tumors, including non-small cell lung cancer, colorectal cancer, gastric cancer, and other cancers, which render it a highly promising target of the treatment for tumors^[1]. LM-24C5 is a bispecific antibody developed by LaNova Medicines based on the conditionally activated 4-1BB platform, which can specifically redirect immune cells to the tumor microenvironment by specifically binding them to CEACAM5 on the surface of tumour cells and 4-1BB on the surface of immune cells, thereby activating and enhancing their anti-tumor activity. The unique structure of LM-24C5 enables the optional activation of the 4-1BB signaling pathway with CEACAM5-dependent approaches, while avoiding the toxicity risks associated with non-specific activation of the peripheral immune system.

Preclinical studies have shown that LM-24C5 can induce durable anti-tumor immune memory, and exhibits synergistic effects when administered in combination with other immunotherapeutic agents, thus indicating its potential to become the First-in-Class immunotherapy. Currently, LM-24C5 is undergoing Phase I/II clinical trials in the United States.

Source:

[1] Clin Cancer Res; 26(24) December 15, 2020; Clin Cancer Res. 2021 March 01; 27(3): 759–774; The Human Protein Atlas

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 August 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.